Provider Summary
Primary Uses
Severe eosinophilic asthma (add-on maintenance) and other eosinophilic disorders per labeled indications and payer criteria.
Mechanism of Action
Anti‑IL‑5 monoclonal antibody reduces eosinophil levels.
Pre-treatment / Baseline Requirement
Confirm eosinophilic phenotype/indication; treat helminth infections when applicable; vaccination review.
Common side effects
Headache, injection-site reactions, back pain, fatigue; herpes zoster has been reported.
Serious adverse effects / key risks
Hypersensitivity reactions; serious infections (rare).
Referral requirements
Standard infusion referral form + drug-specific checklist
Patient & Caregiver Education
What it treats
Severe eosinophilic asthma and other eosinophilic disorders per labeled indications and payer criteria.
How it works
Anti‑IL‑5 monoclonal antibody reduces eosinophil levels.
Before treatment
Tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review.
Common side effects
Headache, injection-site reactions, back pain, fatigue; herpes zoster has been reported.
Get urgent help for:
Hypersensitivity reactions; serious infections.
On treatment Day:
Plan to stay for monitoring. If you feel dizzy, drowsy, or unwell afterward, do not drive and follow your clinician’s instructions.